Ensysce Biosciences, Inc.
ENSC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,840 | $4,911 | $3,587 | $10,004 |
| - Cash | $1,673 | $2,212 | $3,052 | $3,502 |
| + Debt | $388 | $425 | $257 | $302 |
| Enterprise Value | $5,554 | $3,124 | $791 | $6,804 |
| Revenue | $493 | $1,371 | $1,320 | $1,304 |
| % Growth | -64% | 3.9% | 1.3% | – |
| Gross Profit | -$2,462 | -$552 | $1,320 | -$2,499 |
| % Margin | -499.2% | -40.2% | 100% | -191.7% |
| EBITDA | $18 | $0 | -$1,942 | $0 |
| % Margin | 3.7% | 0% | -147.1% | 0% |
| Net Income | -$3,729 | -$1,733 | -$1,946 | -$3,564 |
| % Margin | -756.3% | -126.4% | -147.4% | -273.4% |
| EPS Diluted | -1.29 | -0.79 | -1.39 | -2.9 |
| % Growth | -63.3% | 43.2% | 52.1% | – |
| Operating Cash Flow | -$1,866 | -$2,707 | -$1,707 | -$764 |
| Capital Expenditures | -$124 | $0 | $0 | $0 |
| Free Cash Flow | -$1,990 | -$2,707 | -$1,707 | -$764 |